CDK inhibitor and application thereof

Abstract

The invention discloses application of CDK in preparation and screening of anti-hepatoma drugs, and application of New Tectorigenin as a CDK inhibitor in regulating HepG2 cell cycle. The inventor of the application finds that New Tectorigenin can inhibit proliferation of HepG2 cells by inhibiting synthesis of CDK2, CDK4 and CDK6 proteins in the HepG2 cell cycle, and therefore, as a CDK inhibitor,New Tectorigenin can inhibit proliferation of HepG2, having an important meaning for developing a new generation of anti-hepatoma drugs.

Description

technical field [0001] The invention relates to the technical field of cell engineering, in particular to a CDK inhibitor and its application. Background technique [0002] Primary liver cancer (PLC) is a malignant tumor with rapid disease progression and short survival period. Globally, the incidence and mortality of primary liver cancer rank the seventh and fourth among various malignant tumors, respectively. [1] . The incidence of liver cancer in my country accounts for 45% of the world's total, and the incidence and mortality are also increasing year by year. There are a variety of clinical methods for the treatment of primary liver cancer. At present, the treatment methods for primary liver cancer can be divided into two categories: liver resection and liver transplantation, which play a radical role, and radiotherapy and chemotherapy, which inhibit the growth and proliferation of liver cancer cells. However, most liver cancer patients have entered the advanced stag...

AI Technical Summary

Problems solved by technology

However, New Tectorigenin, as a new anti-liver cancer drug, has not yet explored its specific mechanism of anti-liver cancer

Images